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Abstract 
 
The Akt pathway is an important cell-signaling pathway that can affect many 
cellular processes including growth and proliferation. This study aims to explore the role 
of the Akt pathway in the formation of Muller glia-derived progenitors in the avian 
retina. The results show that pS6 (a readout of the Akt pathway) is expressed in 
embryonic retina but there are minimal levels in a mature, normal retina. Upon 
excitotoxic damage or FGF2 stimulation, pS6 is highly upregulated with a peak at 4h 
after damage. Furthermore, VO-OHpic trihydrate (VOTH), a PTEN inhibitor was able to 
increase the number of proliferating Muller glia four fold. We conclude that the Akt 
pathway is not active in a normal retina, the Akt/mTOR pathway is rapidly activated in 
damaged retinas, and this pathway stimulates the formation of Muller glia-derived 
progenitors. 
 
Introduction 
 
 The retina is derived from the ventral diencephalon and contains the following 
neurons: rods, cones, bipolar, horizontal, bipolar, amacrine and bipolar cells. The primary 
photosensitive cells are the rod and cone cells located in the outer retina. Rods are 
responsible for vision in low light and cones enable color vision. Horizontal cells provide 
lateral inhibition and signal integration for the photoreceptor cells. The bipolar cells are 
responsible for transmitting signals from the photoreceptor cells to the ganglion cells and 
the signals are refined and processed by amacrine cells. Ultimately, the axons of the 
ganglion cells will come together to form the optic nerve to send signals to higher visual 
centers in the brain.  
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The aforementioned neurons that make up the retina are supported by the 
following glial cells: Müller glia, microglia and oligodendrocytes. Müller glia are the 
primary glial cell in the retina and have processes that span the entire length of the retina. 
Furthermore, Müller glia provide structural, metabolic, and synaptic support as well as 
ion homeostasis for the neurons in the retina. Oligodendrocytes are found in the inner 
retina and produce myelin for the axons of the ganglion cells. Lastly, microglia function 
as macrophages helping to rid the retina of any foreign organism or substance. 
Akt, also known as Protein Kinase B (PKB), is the nucleus of a foundational 
signal transduction pathway with a pivotal role in many cellular processes. Cellular 
growth, migration, invasion, survival, proliferation, metabolism and angiogenesis all have 
links to Akt signaling. Furthermore, it has been shown that the Akt pathway 
communicates with other major signaling pathways such as NF-κB, Erk and JNK/p38, 
each of which having their own separate downstream effects on cellular processes 
(Manning and Cantley 2007). With far-reaching and well-studied effects, the Akt 
pathway can be selectively activated or inhibited with many different pharmacological 
agents. This paper will primarily focus on Akt signaling in the avian retina. 
 In previous works, it has been shown that excitotoxic damage (Fischer and Reh 
2001) as well as FGF2/insulin in the absence of damage (Fischer et al. 2002) can drive 
the de-differentiation of Müller glia into progenitor cells in the avian retina and that these 
progenitor cells can then re-differentiate into amacrine and bipolar cells. Such findings 
can eventually be translated into potential cell-replacement therapies for degenerative 
retinal diseases.  Therefore, I would like to further pursue the task of unraveling the 
complexities of the de-differentiation to re-differentiation pathways. The main goal of the 
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current study was to examine Akt signaling in a normal and stimulated avian retina as 
well as the pathway’s role in the formation of Müller glia derived progenitors. 
Phosphorylated S6 protein (pS6), a component of the mammalian 40S ribosomal 
subunit, was chosen as a downstream readout of the Akt pathway. S6 Kinase (S6K) is 
responsible for the translational control of 5’TOP mRNAs that code for translational 
machinery and elongation factors necessary for cell proliferation and growth. S6 is 
regulated by S6K through multiple phosphorylations (Dufner and Thomas 1999). 
VO-OHpic trihydrate (VOTH), a small molecule PTEN inhibitor was chosen to 
manipulate the Akt pathway. Inhibition of PTEN would allow for the uncontrolled 
phosphorylation of PIP2 to PIP3 by PI3 Kinase, leading to the successive activation of 
Akt, mTORC1, p70S6 kinase [the cytoplasmic isoform of S6K (Dufner and Thomas 
1999)] and ultimately the phosphorylation of S6 as shown in the diagram below (Sawyers 
2008). 
                            
The phosphatidylinositol-3-OH kinase 
(PI(3)K)–PTEN–mTOR signalling pathway is 
aberrantly activated in many tumors, leading to 
dysregulation of cell growth and proliferation. 
Activation of the pathway can be assessed by 
biomarkers such as loss of PTEN mRNA or 
protein production in tumor tissue. 
Biochemical inhibition of mTOR by rapamycin 
can be assessed by biomarkers such as the 
abundance of the phosphorylated form of the 
ribosomal protein S6, and its therapeutic effects 
on tumor cells can be assessed by the 
proliferation marker Ki-67. IRS, insulin-
receptor substrate; S6K1, ribosomal protein S6 
kinase, 70-kDa, polypeptide 1 (Sawyers 2008).  
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 Different branches of the Akt pathway. Taken from Cell Signaling. 
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Materials and Methods 
 
Animals 
 
The use of animals was in accordance with the guidelines established by the 
National Institutes of Health and the Ohio State University. Newly hatched leghorn 
chickens (Gallus gallus domesticus) were obtained from the Department of Animal 
Sciences at the Ohio State University and kept on a cycle of 12-h light, 12-h dark (lights 
on at 7:00 a.m.). Chicks were housed in a stainless steel brooder at about 28°C and 
received water and PurinaTM chick starter ad libitum. 
 
 
Intraocular Injections 
 
Intraocular injections were performed as described previously (Fischer et al., 
2009). In all experiments, 20 µL of vehicle containing the test compound was injected 
into the experimental (right) eye, and 20 µL of vehicle alone was injected into the control 
(left) eye. The vehicle was DMSO (Dimethyl sulfoxide; 30% DMSO in saline). Test 
compounds included NMDA (N-methyl-D-aspartate; 20 µmol (full) and 5 µmol (quarter) 
per dose; Sigma-Aldrich), recombinant human FGF2 (250 ng/dose; R&D Systems), 
VOTH (VO-OHpic trihydrate; 1µg/dose; Sigma-Aldrich). 
We used six different injection paradigms: (1) Paradigm A—on post-hatch day 8 
(P8) the left eye received a single injection of saline and the right eye received VOTH. 
Retinas were harvested 1, 2, 4, and 24h later. (2) Paradigm B—on P7 the left eye 
received an injection of saline and the right eye received VOTH. Retinas were harvested 
4h and 48h later. (3) Paradigm C—on P7 both the left and right eyes received a quarter 
dose of NMDA. Then, 4h later, the right eye received a dose of VOTH. 24h after the 
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injection of VOTH, the right retina was given a second dose of VOTH. 48h after the first 
VOTH injection, the right retina received a dose of VOTH+BrdU. The retinas were 
harvested 72h after the first dose of VOTH. (4) Paradigm D – on P7 the left eye received 
injections of saline and the right eye received two consecutive daily doses of FGF2. The 
retinas were harvested 2 days after the first injection of FGF2. (5) Paradigm E – on P7 the 
left eye received saline and the right eye was treated with a full dose of NMDA. Retinas 
were then harvested 1, 2, and 3 days after the first injection of NMDA. (6) Paradigm F – 
on P8 the left eye received saline and the right eye received a quarter dose of NMDA. 
The retinas were harvested 4h later. 
Fixation, Sectioning and Immunocytochemistry 
 
Tissue dissection, fixation, cryosectioning, and immunolabeling were performed 
as described previously (Fischer et al., 1998, 2009).  
Working dilutions and sources of antibodies used in this study included; rabbit 
anti-pS6 was used at 1:750 (2215S; Cell Signaling Technologies); rabbit anti-pERK1/2 
was used at 1:200 (137F5; Cell Signaling Technologies); rabbit anti-pCREB was used at 
1:600 (87G3; Cell Signaling Technologies); goat anti-Sox2 was used at 1:1,000 (Y-17; 
Santa Cruz Immunochemicals); mouse anti-Brn3a was used at 1:50 (Chemicon; 
MAB1585); rabbit anti-TFBP was used at 1:400 (Dr. J.J. Lucas; SUNY); rat anti-BrdU 
was used at 1:200 (OBT0030S; Serrotec). Secondary antibodies included donkey-anti-
goat- Alexa488, goat-anti-rabbit-Alexa488, goat-anti-mouse- Alexa488/568, rabbit anti-
goat Alexa488 and diluted to 1:1,000 in PBS plus 0.2% Triton X-100. 
 
 
	   8	  
Cell-distinguishing markers in the retina 
 pS6 is marker of the activated Akt pathway. Sox2 is expressed by Müller 
glia and cholinergic amacrine cells. Brn3a is expressed ganglion cells. TFBP is expressed 
by oligodendrocytes. pCREB and pERK are readouts of the activated MAPK pathway. 
HuC/D is expressed amacrine and ganglion cells. Bromodeoxyuridine (BrdU) is a 
thymidine analog that gets incorporated into DNA during DNA replication. 
 
Photography, Measurements, Cell Counts, and Statistical Analyses 
 
Photomicrographs were taken by using a Leica DM5000B microscope equipped 
with epifluorescence and a 12 megapixel Leica DC500 digital camera. Identical 
illumination, microscope and camera settings were used to obtain images for 
quantification. Images were optimized for color, brightness and contrast, and double-
labeled images overlaid by using Adobe PhotoshopTM6.0. Areas were sampled from 5.4 
MP digital images. BrdU cell counts were made from four different animals. Due to inter-
animal variability, all counts were standardized by (treated/control) *100. To avoid the 
possibility of region-specific differences within the retina, cell counts were consistently 
made from the same region of retina (21,2600µ2) for each data set.  
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Results 
 
 Since pS6 was chosen as a readout of the Akt pathway, it was important to 
establish a baseline for pS6 expression in an untreated retina. pS6-immunoreactivity is 
present in the axon terminals of the photoreceptors (bright green band in fig 1a).  The 
labeling in the axon terminals of photoreceptors is likely to be a non-specific cross-
reaction, given that this pattern of labeling is not perturbed by experimental paradigms 
that are expected to influence levels of pS6.  In addition, pS6-immunoreactivity was 
observed in a few ganglion cells [positive for the ganglion cell marker Brn3a (fig 1f,i)] 
and oligodendrocytes [positive for TFBP (fig 1l)].  pS6 was not observed in Sox2-
expressing mature Müller glia in the inner nuclear layer (INL) (fig 1b,c).  
In addition to mature retinas, patterns of pS6 expression were determined in 
embryonic retinas. Eggs were incubated and harvested at embryonic day 4 (E4), E6, E8, 
E12 and E15. At E4 and E6, during early stages of retinal development, pS6 is primarily 
expressed in maturing ganglion cells, as evidenced by pS6 positive cells which are also 
positive for HuD/C, a cytoplasmic neuronal marker (fig 2f,i). By E8, there is continued 
pS6 staining in maturing neurons, but also in presumptive progenitors in the developing 
INL (fig 2c). At E12, pS6 is present in relatively few maturing neurons and appears in a 
few scattered Müller glia (fig 2j). Furthermore, a few cell in the cilliary marginal zone 
(CMZ; contains retinal progenitors) display pS6 expression (fig 2k).  Interestingly, at E15 
pS6 appears to be highly expressed in maturing Müller glia (Fig. 2l). 
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Figure. 1. pS6 expression in a normal retina. Retinas were harvested 4 hours after injection with 
sterile saline. (a-c) pS6, Sox2 expression and colocalization in a normal retina. (d-i) pS6, Brn3a and 
colocalization in a normal retina. (j-l) pS6, TFBP expression and colocalization in a normal retina. 
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Figure. 2. pS6, Sox2 and HuD/C expression in the embryonic retina. a-c) pS6 expression at E4, E6, E8. d-
i) Expression of pS6, HuD/C and colocalization at E4 (d-f) and E6 (g-i). j) Colocalization of pS6 and Sox2 
and E12. k) Expression of pS6 in the CMZ at E12. l) colocalization of pS6 and Sox2 at E15. 
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Next, retinas were damaged with N-methyl-D-aspartate (NMDA; 0.5 µmol 
NMDA; fig 3a-d, or 2 µmol NMDA; fig 3e-p) which is an excitotoxin that primarily kills 
amacrine cells (Fischer and Reh 2001). The retinas were harvested at 4h (fig 3a-d), 1 day 
(fig 3e-h), 2 days (fig 3i-l) and 3 days (fig 3m-p) after injection with NMDA. Expression 
of pS6 in the control central retina is relatively low (fig 3a,e,i,m) with only a slight 
increase in peripheral regions of control retinas from eyes injected with saline (fig 
3c,g,k,o). Upon damage, there is a large upregulation of pS6 in the INL in both central 
and peripheral retina at 4h (fig 3b, d) and 1 day (fig 3f, h) with no noticeable difference 
between central and peripheral.	   Expression levels of pS6 taper off in the damaged central 
retina by day 2 (fig 3j), with a decreased level of pS6 in the treated periphery (fig 3l) as 
compared with 4h and 1 day after NMDA injection. By day 3, there is only slight pS6 
expression in the central and peripheral treated retinas (fig 3n,p) and wild type pS6 levels 
in both the central and peripheral control retinas (compare fig 3m,o to fig 1a,c). 
It was previously shown that a combined injection of FGF2 and insulin causes the 
Müller glia to become proliferating progenitor cells in the same manner as in NMDA-
damaged retinas (Fischer et al. 2002).  Injections of FGF2 alone are known to enhance 
the ability of Müller glia to become progenitor cells (Fischer et al. 2009a); (Ghai et al. 
2010). Thus, we tested whether FGF2 influenced the expression of pS6.  Retinas were 
injected with two consecutive daily doses of FGF2 (250 ng) and harvested 2 days after 
the first injection of FGF2. This caused an increase in pS6 expression in the INL similar 
to the levels seen in the central retina after 1 day of NMDA damage (compare fig 4d to 
fig 3f). The cells expressing pS6 are Sox2-positive Muller glia (fig 4f). 
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Figure. 3. Expression of pS6 and Sox2 after NMDA damage. For a-d, retinas were given a quarter dose 
(0.5 µmol) of NMDA at P8. For e-p, retinas were given a full dose (2.0 µmol) of NMDA at P7. The control 
retinas were given sterile saline. The retinas were harvested at 4h (a-d), 1 day (e-h), 2 days (i-l) and 3 days 
(m-p) after injection with NMDA. (a-p) Colocalization of pS6 and Sox2 in the central and peripheral retina 
at 4h (a-d), 1 day (e-h), 2 days (i-l), 3 days (m-p). 
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Figure. 4. FGF2 induced expression of pS6. The control retinas were given sterile saline and the treated 
retinas received 2 doses of FGF2 (250 ng). (a-c) Expression of pS6, Sox2 and colocalization in the control 
retina. (d-f) Expression of pS6, Sox2 and colocalization in the treated retina.  
 
The next step in these experiments was to assay the effects of PTEN-inhibitor 
(VOTH) in the retina. VOTH was injected and retinas were harvested 1h, 2h, 4h, 1 day 
and 2 days after injection with VOTH. To assess the specificity of the PTEN inhibitor, 
we probed for off-target effects and determined whether MAPK-signaling was affected in 
the Müller glia; a read-out of glial reactivity (Fischer et al. 2009a/b). Both pCREB (fig 
5a-d) and pERK (fig 5e-h) were expressed in the central and peripheral retina. There 
were no consistent expression patterns of pCREB (fig 5a-d) across all time points (1hr, 
2h, 4h, 1 day and 2 days). Furthermore, there were no differences in pERK expression in 
the central and peripheral retina (fig 5e-h). Overall expression levels of pCREB and 
pERK were low as compared to a previous work (Fischer et al. 2009a). There does not 
appear to be a difference in pS6 levels between retinas treated with VOTH (fig 5j,l) and 
the control (fig 5i,k), suggesting that PI3K-signaling may be very low in normal, healthy 
retinas.    
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Figure. 5. VOTH treatement. The pERK, pS6, pCREB retinas were harvested 1h, 4h and 4h respectively after 1 
dose of VOTH (1.0 µg). The control retinas were given sterile saline. (a-d) pCREB expression in the central and 
peripheral retina. (e-h) pERK expression in the central and peripheral retina. (i-l) pS6 expression in the central and 
peripheral retina. 
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pS6 is highly up regulated in Müller glia in NMDA-damaged retina, suggesting 
that PI3K/Akt/mTOR-signaling is activated.  Accordingly, we tested whether further 
activation of this pathway with VOTH influenced the formation of proliferating Müller 
glia-derived progenitors. Retinas were injected with 0.5 µmol of NMDA followed by a 
dose of VOTH 4h later. 24h later, another dose of VOTH was administered. Then, 48h 
after the first injection with VOTH, a dose of VOTH+BrdU was given and the retinas 
were harvested 72h after the first VOTH injection. The VOTH appeared to slightly 
increase levels of pS6 in peripheral regions of the NMDA-damaged retinas (Fig. 6b,d). 
Injection of BrdU allowed for the marking of proliferating cells.  Retinal areas of 
21,2600µ2 were surveyed and cells positive for both BrdU and Sox2 in the INL 
(proliferating Muller glia) were counted.  NMDA-damaged retinas treated with VOTH 
had an average of 427% and 139% increase in number of Sox2/BrdU-positive Müller glia 
in central (n=4) and peripheral retina (n=3) respectively (fig 6f,h; fig 6i).  
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Figure. 6. VOTH after NMDA damage. Both control and treated retinas were given a quarter dose (0.5 µmol) 
of NMDA. 4h later the treated retinas received a single dose of VOTH (1.0 µg). 24h after the first dose of 
VOTH, the treated retinas received another dose of VOTH. 48h after the first injection of VOTH, the retinas 
received a dose of VOTH+BrdU. The retinas were harvested 72h after the first injection of VOTH. An area of 
21,2600µ2 pixels was used for the BrdU cell counts. (a-d) pS6 expression in the central and peripheral retina. 
(e-h) BrdU and Sox2 colocalization in the central and peripheral retina. (i) A histogram illustrating the means 
and standard deviations for the % change in BrdU, Sox2-positive cells in the INL (proliferating Müller glia) 
in the central and peripheral retina. Significance (*P < 0.05) of difference was calculated using a 1-tailed 
students t-test. 
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Discussion 
 
 The results show that pS6 is only expressed in a small subset of ganglion cells and 
oligodendrocytes in normal chick retina. The data from embryonic retinas suggests that 
expression of pS6 is symptomatic of immature neurons and glia because it is expressed in 
immature ganglion cells, E8 progenitors and maturing Muller glia. There is a significant 
increase in pS6 expression upon damage with NMDA, and FGF2 stimulation indicating 
that pS6 expression is not solely a response to acute retinal damage. Furthermore, 
following NMDA-treatment, pS6 expression peaks at 4h suggesting that the 
PI3K/Akt/mTOR pathway is rapidly activated in Müller glia after damage to retinal 
neurons. 
 VOTH by itself does not induce a response in the retina as evidenced by the 
inconsistent expression of pCREB, and normal levels pERK and pS6 in Müller glia.  This 
finding suggests that there is normally little or no PI3K-signaling in normal, healthy 
Müller glia and that VOTH specifically acts on the Akt pathway.  However, in NMDA-
damaged retinas, VOTH caused an increase in proliferating Muller glia-derived 
progenitors.  It is expected that the VOTH should increase retinal levels of pS6 in 
damaged retinas.  However we failed to detect large, widespread increases in pS6 at 3 
days after NMDA-treatment.  Further, experiments are required to test whether levels of 
pS6 in Müller glia are affected by VOTH shortly after NMDA-treatment when levels are 
normally elevated following damage. 
 In conclusion, the results indicate that Akt signaling is not active in a normal 
retina and that pS6 is a reliable readout of the pathway. Akt signaling is selectively 
activated in Müller glia in response to NMDA damage as well as FGF2 stimulation.  
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Further, enhanced activation of the PI3K pathway by inhibiting PTEN in Müller glia 
increased the number of proliferating glia-derived progenitors. 
 The results of these experiments provide a foundation for understanding 
Akt/mTOR signaling during retinal development and following retinal damage.  In 
addition, these studies suggest that PTEN can be targeted pharmacologically to enhance 
the formation of Müller glia-derived progenitors and, possibly, neuronal regeneration.  
The next step, with regards to the increased levels of Müller glia proliferation (BrdU, 
Sox2-positive cells in the INL), would be a TUNEL stain in order to determine if VOTH 
has neuro-protective qualities. Furthermore, there is evidence to support that Oct4, Akt 
and Hmgb2 form a feedback loop to maintain pluripotency in mouse embryonic stem 
cells (Campbell and Rudnicki 2013). Therefore, there should be staining or RT-PCR for 
Oct4, Klf4 and Nanog (all pluripotency factors) in order to determine whether the 
dedifferentiating Müller glia are expressing pluripotency factors.  
 Additionally, new injection paradigms should be used. The retinas should be 
damaged with NMDA and then injected with rapamycin, an inhibitor of mTORC1, 
theoretically leading to the down regulation of pS6 expression. This paradigm can be 
modified by administering VOTH before the rapamycin in order to determine whether the 
inhibition of mTORC1 can negate the activating effect of VOTH. If pS6 levels are found 
to be high, that result would indicate that pS6 activation is occurring by a secondary 
signal transduction pathway. Lastly, VOTH can be injected after FGF2 + insulin, in order 
to determine whether the formation of Müller glia-derived progenitors can be enhanced 
by further activating the Akt/mTOR pathway in the absence of retinal damage. 
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